[Federal Register Volume 89, Number 198 (Friday, October 11, 2024)]
[Notices]
[Pages 82628-82629]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23597]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness 
Consortium

    Notice is hereby given that, on July 11, 2024, pursuant to section 
6(a) of the National Cooperative Research and

[[Page 82629]]

Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), 
Biopharmaceutical Manufacturing Preparedness Consortium (``BioMaP-
Consortium'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, Arena BioPharma Consulting LLC, Athens, GA; 
ReechPharma LLC, Newark, CA; Repligen Corp., Waltham, WA; RexSter 
Technologies, Inc., Acton, MA; VJ Technologies, Inc., Bohemia, NY; 
Altor Safety LLC, Valley Cottage, NY; Anverra Pharma LLC, Mt. Pleasant, 
SC; Arranat Bio MA LLC, Watertown, MA; BioTechnique LLC, York, PA; 
Celltheon, Union City, CA; CHO Plus, Inc., South San Francisco, CA; 
Cocoon Bioscience S.L., Derio, SPAIN; CONTINUUS Pharmaceuticals, Inc., 
Woburn, MA; Convergence, Oklahoma City, OK; DNA Script, Daly City, CA; 
Evonik Corp., Piscataway, NJ; Gerresheimer Glass, Inc., Vineland, NJ; 
Innoviva Specialty Therapeutics, Waltham, MA; KBI Biopharma, Durham, 
NC; Orexo AB, Morristown, NJ; Persist AI Formulations Corp., West 
Sacramento, CA; Phenom Pharmaceuticals LLC, Miami Beach, FL; Shionogi, 
Inc., Florham Park, NJ; Solaris Vaccines, Inc., Fort Collins, CO; 
Spring Discovery, Inc., San Carlos, CA; Sublime LLC, Ann Arbor, MI, 
Watson-Marlow, Inc., Wilmington, MA; Apotex Corp., Weston, FL; Avid 
Bioservices, Inc., Tustin, CA; Burrell International Group LLC, 
Washington, DC; Dark Wolf Solutions LLC, Herdon, VA; GENEVATIONUS LLC, 
Sacramento, CA; Gusmer Enterprises, Inc., Mountainside, NJ; Integrated 
Pharma Services, Rockville, MD; Replicate Bioscience, San Diego, CA; 
Seqirus, Inc., Holly Springs, NC; Signet Healthcare Management LLC, New 
York, NY; Sterigenics Radiation Technologies LLC, Oak Brook, IL; The 
Albert B. Sabin Vaccine Institute, Inc., Washington, DC; Virica 
Biotech, Ottawa, CANADA; Agile GxP Technologies, Providence, RI; Allied 
Technologies and Consulting LLC, Frederick, MD; Global Key Solutions 
Corp., Dalton, PA; Industrial Info Resources, Inc., Sugar Land, TX; 
Prince Sterilization Services LLC, Pine Brook, NJ; Curia Global, Inc., 
Albany, NY; Donaldson Company, Inc., Bloomington, MN; GCM Pharma, St. 
Louis, MO; Photosynthetic B.V., Amsterdam, NETHERLANDS; Revagenix, 
Inc., San Francisco, CA; Agno Pharmaceuticals LLC, Bethlehem, PA; 
BioAnalysis LLC, Philadelphia, PA; Cornerstone Government Affairs, 
Inc., Washington, DC; Cytophage Technologies, Inc., Winnipeg, CANADA; 
Humanetics Corp., Edina, MN; NorthX Biologics AB, Matfors, SWEDEN; 
Novavax, Inc., Gaithersburg, MD; Quantiscope PBC, Salt Lake City, UT; 
Stoic Bio, Inc., San Diego, CA; and Sunflower Therapeutics PBC, 
Hingham, MA, have been added as parties to this venture.
    Also, Quantum Four Labs LLC, Arcadia, CA, has withdrawn as party to 
this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and the BioMaP-Consortium intends to 
file additional written notifications disclosing all changes in 
membership.
    On January 5, 2024, the BioMaP- Consortium filed its original 
notification pursuant to section 6(a) of the Act. The Department of 
Justice published a notice in the Federal Register pursuant to section 
6(b) of the Act on April 16, 2024 (89 FR 26923).
    The last notification was filed with the Department on April 12, 
2024. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on June 21, 2024 (89 FR 52097).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-23597 Filed 10-10-24; 8:45 am]
BILLING CODE P